Insulin Glargine/Lixisenatide
Brand name: Soliqua 100-33
Rank #170 of 500 drugs by total cost
$92.5M
Total Cost
82,886
Total Claims
$92.5M
Total Cost
2,854
Prescribers
$1,116
Cost per Claim
9,518
Beneficiaries
135,096
30-Day Fills
$32K
Avg Cost/Provider
29
Avg Claims/Provider
About Insulin Glargine/Lixisenatide
Insulin Glargine/Lixisenatide (sold as Soliqua 100-33) was prescribed 82,886 times by 2,854 Medicare Part D providers in 2023, costing the program $92.5M. At $1,116 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 167 | Sevelamer Carbonate (Sevelamer Carbonate) | $95.6M | 277,192 |
| 168 | Aripiprazole Lauroxil (Aristada) | $93.3M | 31,120 |
| 169 | Trazodone Hcl (Trazodone Hcl) | $92.6M | 7,273,528 |
| 170 | Insulin Glargine/Lixisenatide (Soliqua 100-33) | $92.5M | 82,886 |
| 171 | Latanoprost (Latanoprost) | $92.3M | 4,388,601 |
| 172 | Ribociclib Succinate (Kisqali) | $90.3M | 5,978 |
| 173 | Lacosamide (Lacosamide) | $90.1M | 300,038 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology